The U.S. Food and Drug Administration has announced a series of actions designed to accelerate and modernize clinical research across the drug-development continuum, from the Investigational New Drug stage through late-stage pivotal trials.
The work is outlined under Operation TrialBlazer, a U.S. Department of Health and Human Services initiative focused on reducing unnecessary regulatory burden, clarifying phase-appropriate expectations, and supporting more efficient clinical development while maintaining regulatory rigor and participant protections.
A New Focus on Early Clinical Development
The FDA said its early-stage actions are intended to help ensure that the United States remains a global leader in pharmaceutical innovation. The agency plans to work with government partners, academic medical centers, contract research organizations, and the private sector to improve the pathway from drug identification to first-in-human studies.
A central component is the proposed Expedited Investigational New Drug Pilot Program.
Under the proposed pilot, drug sponsors would work with qualified research institutions, including academic medical centers and contract research organizations, to prepare Phase 1 IND submissions for first-in-human clinical trials.
The program would use a rolling IND submission platform intended to create a more flexible pre-IND process, improve submission quality, and reduce the likelihood of clinical holds. Before launching the initiative, the FDA is seeking public feedback.
Supporting Smaller Companies Through the IND Process
Preparing an IND application can be particularly challenging for smaller companies without extensive regulatory teams.
To address this, the FDA has introduced a Phase 1 IND Navigator webpage, which brings together guidance documents, regulatory requirements, practical examples, and additional resources for companies preparing IND submissions to the FDA’s Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research.
The goal is to make key information easier to access at a stage when development decisions can shape the course of an entire clinical program.
Right-Sized CMC Requirements for First-in-Human Studies
The FDA has also updated its Phase 1 Chemistry, Manufacturing, and Controls webpage for CDER-regulated drugs.
According to the agency, some companies have historically submitted more data than is necessary at the first-in-human IND stage, creating additional work and delaying entry into early clinical trials.
The updated resource clarifies phase-specific CMC expectations for first-in-human Phase 1 INDs. By focusing on data needed at that point in development, the FDA stated that companies may save six to 12 months of development time.
Moving Beyond Traditional Starting-Dose Approaches
Another major early-stage action is the release of draft guidance on Quantitative Systems Pharmacology-Based Dose Selection for Minimum Anticipated Biological Effect Level in First-in-Human Trials.
Selecting an appropriate starting dose remains one of the most important decisions in first-in-human research. The draft guidance focuses on newer therapies with complex mechanisms of action and supports the use of quantitative systems pharmacology to guide dose selection.
It is primarily intended for products for which the minimum anticipated biological effect level approach is recommended.
The FDA described this as part of a continuing shift away from historical approaches that rely primarily on animal toxicology studies to select starting doses for first-in-human trials.
Building on Recent FDA Actions
The agency noted that these actions build on several recent efforts to streamline early-stage development.
In June 2026, the FDA issued draft guidance for developers of cell and gene therapies, clarifying how sponsors may build on existing findings rather than repeat costly studies.
In May 2026, the FDA released draft guidance recommending streamlined nonclinical safety assessment approaches for certain oncology pharmaceuticals. The work forms part of a broader initiative to reduce animal testing through New Approach Methodologies, including human organ-on-a-chip systems, real-world data, and computational models.
The FDA also released a report in April 2026 summarizing its progress in implementing these methodologies.
Late-Stage Development: Updating the Evidence Framework
Operation TrialBlazer also includes measures for late-stage clinical development.
The FDA revised its draft guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products. The revised document clarifies situations in which a drug developer may be able to rely on one rigorous, adequate, and well-controlled pivotal clinical investigation, together with confirmatory evidence, to establish substantial evidence of effectiveness for approval.
The agency stated that advances in the understanding of biological processes and the growing availability of high-quality data have changed the evidence landscape for drug development.
Master Protocols Take a Larger Role
The FDA also revised its draft guidance on Master Protocols for Drug and Biological Product Development.
The update includes information on basket trials, in which one drug may be evaluated across multiple diseases, conditions, or disease subtypes. It also addresses umbrella trials and platform trials, which can evaluate multiple drugs under one protocol structure.
By bringing several investigations under a single framework, master protocols may reduce duplicative infrastructure, streamline data collection, and support the generation of evidence needed for regulatory decision-making.
An Ongoing Regulatory Effort
The FDA emphasized that Operation TrialBlazer is an ongoing and iterative effort. The agency said it will continue working with stakeholders and updating its approach to ensure that its guidance remains science-based, relevant, and responsive to the realities of modern drug development.
Written by Nare Hovhannisyan, MD
Stay informed with more articles like this on OncoDaily